Clovis Gets Creamed After Cancer Drug Failure

Clovis (NAS: CLVS) was forced to admit an unpleasant defeat after data emerged showing no significant difference in survival rates for advanced pancreatic cancer patients treated with the company's drug candidate CO-101 versus the current chemotherapy treatment, gemcitabine. The news caused the stock to drop by nearly 40% on Monday. In this video, Motley Fool health care analyst Brenton Flynn tells us how the company plans to move forward in the face of these big losses, and why this has been a difficult space for other companies as well.

While you can certainly make huge gains in biotech and pharmaceuticals, stocks like Clovis show that the potential for huge gains often goes hand in hand with huge risk. That's why we believe that the best investing approach is to choose great companies and stick with them for the long term. In our free report "3 Stocks That Will Help You Retire Rich," we name stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

The article Clovis Gets Creamed After Cancer Drug Failure originally appeared on Fool.com.

Brenton Flynn has no positions in the stocks mentioned above. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.